Top

Published in:

01-04-2012 | IM - REVIEW

Recent advances in understanding ulcerative colitis

Authors: Antonio Di Sabatino, Paolo Biancheri, Laura Rovedatti, Thomas Thornton MacDonald, Gino Roberto Corazza

Published in: Internal and Emergency Medicine | Issue 2/2012

Abstract

Ulcerative colitis, one of the two main forms of inflammatory bowel disease, is characterized by inflammation of the large bowel with constant involvement of the rectum, and a possible continuous retrograde distribution up to the cecum. Typical macroscopic lesions are mucosal ulcerations, with immune cell infiltration and cryptic abscesses at histology. Ulcerative colitis usually manifests with bloody diarrhea, is associated with a number of extra-intestinal manifestations, and may be acutely complicated by toxic megacolon. Longstanding disease may predispose to the development of colorectal cancer. Therapeutic options include mesalazine, corticosteroids, immunomodulators and biologic agents; however, if these treatments fail, the only available therapeutic choice remaining is the surgical removal of the colon. This review emphasizes novel concepts in the basic aspects of ulcerative colitis, and, in addition to the current clinical and diagnostic knowledge, it also describes new treatment options for this condition.

Cosnes J, Gower-Rousseau C, Seksik P et al (2011) Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140:1785–1794PubMedCrossRef

Bernstein CN, Shanahan F (2008) Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut 57:1185–1191PubMedCrossRef

Anderson CA, Boucher G, Lees CW et al (2011) Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 43:246–252PubMedCrossRef

UK IBD Genetics Consortium, Barrett JC, Lee JC et al (2009) Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet 41:1330–1334PubMedCrossRef

McGovern DP, Gardet A, Törkvist L et al (2010) Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 42:332–337PubMedCrossRef

Sabath E, Negoro H, Beaudry S et al (2008) Galpha12 regulates protein interactions within the MDCK cell tight junction and inhibits tight-junction assembly. J Cell Sci 121:814–824PubMedCrossRef

Rovedatti L, Kudo T, Biancheri P et al (2009) Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 58:1629–1636PubMedCrossRef

Boyko EJ, Perera DR, Koepsell TD et al (1988) Effects of cigarette smoking on the clinical course of ulcerative colitis. Scand J Gastroenterol 23:1147–1152PubMedCrossRef

Koutroubakis IE, Vlachonikolis IG, Kouroumalis EA (2002) Role of appendicitis and appendectomy in the pathogenesis of ulcerative colitis: a critical review. Inflamm Bowel Dis 8:277–286PubMedCrossRef

10.

Radford-Smith GL, Edwards JE, Purdie DM et al (2002) Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn’s disease. Gut 51:808–813PubMedCrossRef

11.

Katschinski B, Fingerle D, Scherbaum B et al (1993) Oral contraceptive use and cigarette smoking in Crohn’s disease. Dig Dis Sci 38:1596–1600PubMedCrossRef

12.

Chan SS, Luben R, Bergmann MM et al (2011) Aspirin in the aetiology of Crohn’s disease and ulcerative colitis: a European prospective cohort study. Aliment PharmacolTher 34:649–655CrossRef

13.

Meyer AM, Ramzan NN, Heigh RI et al (2006) Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci 51:168–172PubMedCrossRef

14.

Di Sabatino A, Biancheri P, Rovedatti L et al (2011) New pathogenic paradigms in inflammatory bowel disease. Inflamm Bowel Dis [Epub ahead of print]

15.

Naito Y, Takagi T, Yoshikawa T (2007) Neutrophil-dependent oxidative stress in ulcerative colitis. J Clin Biochem Nutr 41:18–26PubMedCrossRef

16.

Carlson M, Raab Y, Seveus L et al (2002) Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis. Gut 50:501–506PubMedCrossRef

17.

Pender SL, MacDonald TT (2004) Matrix metalloproteinases and the gut: new roles for old enzymes. Curr Opin Pharmacol 4:546–550PubMedCrossRef

18.

Neurath MF, Finotto S, Glimcher LH (2002) The role of Th1/Th2 polarization in mucosal immunity. Nat Med 8:567–573PubMedCrossRef

19.

Di Sabatino A, Rovedatti L, Vidali F et al (2011) Recent advances in understanding Crohn’s disease. Intern Emerg Med [Epub ahead of print]

20.

Fuss IJ, Heller F, Boirivant M et al (2004) Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 113:1490–1497PubMed

21.

Heller F, Florian P, Bojarski C et al (2005) Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129:550–564PubMed

22.

Moum B, Ekbom A, Vatn MH et al (1999) Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol 94:1564–1569PubMedCrossRef

23.

Rothfuss KS, Stange EF, Herrlinger KR (2006) Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 12:4819–4831PubMed

24.

Gan SI, Beck PL (2003) A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol 98:2363–2371PubMedCrossRef

25.

Lakatos PL, Lakatos L (2008) Risk for colorectal cancer in ulcerative colitis: changes causes and management strategies. World J Gastroenterol 14:3937–3947PubMedCrossRef

26.

Triantafillidis JK, Nasioulas G, Kosmidis PA (2009) Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res 29:2727–2737PubMed

27.

Sutherland LR, Martin F, Greer S et al (1987) 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92:1894–1898PubMed

28.

Lewis JD (2011) The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 140:1817–1826PubMedCrossRef

29.

Itzkowitz SH, Present DH, Crohn’s and Colitis Foundation of America Colon Cancer in IBDSG (2005) Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 11:314–321

30.

Zalis M, Singh AK (2004) Imaging of inflammatory bowel disease: CT and MR. Dig Dis 22:56–62PubMedCrossRef

31.

Charron M (1999) Technetium leukocyte imaging in inflammatory bowel disease. Curr Gastroenterol Rep 1:245–252PubMedCrossRef

32.

Spier BJ, Perlman SB, Reichelderfer M (2009) FDG-PET in inflammatory bowel disease. Q J Nucl Med Mol Imaging 53:64–71PubMed

33.

Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology (2004) Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 99:1371–1385PubMedCrossRef

34.

Rutgeerts P, Sandborn WJ, Feagan BG (2005) Infliximab induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476PubMedCrossRef

35.

Van Assche G, Vermeire S, Rutgeerts P (2008) Treatment of severe steroid refractory ulcerative colitis. World J Gastroenterol 14:5508–5511PubMedCrossRef

36.

Baumgart DC, Macdonald JK, Feagan B (2008) Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev 3:CD007216PubMed

37.

Seow CH, Newman A, Irwin SP et al (2010) Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 59:49–54PubMedCrossRef

38.

Di Sabatino A, Liberato L, Marchetti M et al (2011) Optimal use and cost effectiveness of biologic therapies in inflammatory bowel disease. Intern Emerg Med 6(Suppl 1):S17–S27

39.

Oussalah A, Laclotte C, Chevaux JB et al (2008) Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 28:966–972PubMedCrossRef

40.

Afif W, Leighton JA, Hanauer SB et al (2009) Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 15:1302–1307PubMedCrossRef

41.

Sklyarov AY, Panasyuk NB, Fomenko IS (2011) Role of nitric oxide-synthase and cyclooxygenase/lipooxygenase systems in development of experimental ulcerative colitis. J Physiol Pharmacol 62:65–73PubMed

42.

Tang T, Targan SR, Li ZS et al (2011) Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis: a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther 33:194–202PubMedCrossRef

43.

Yang LP, McCormack PL (2011) MMX^® Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis. Drugs 71:221–235PubMedCrossRef

44.

Velayos FS, Terdiman JP, Walsh JM (2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100:1345–1353PubMedCrossRef

45.

Gisbert JP, Linares PM, McNicholl AG et al (2009) Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 30:126–137PubMedCrossRef

46.

Ei-Matary W, Vandermeer B, Griffiths AM (2009) Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 3:CD007560

47.

Berg DF, Bahadursingh AM, Kaminski DL et al (2002) Acute surgical emergencies in inflammatory bowel disease. Am J Surg 184:45–51

48.

Larson DW, Pemberton JH (2004) Current concepts and controversies in surgery for IBD. Gastroenterology 126:1611–1619PubMedCrossRef

49.

Magro F, Lopes S, Rodrigues S et al (2011) How to manage pouchitis in ulcerative colitis? Curr Drug Targets 12:1454–1461

50.

Gionchetti P, Rizzello F, Venturi A et al (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119:305–309PubMedCrossRef

Title: Recent advances in understanding ulcerative colitis
Authors: Antonio Di Sabatino
Paolo Biancheri
Laura Rovedatti
Thomas Thornton MacDonald
Gino Roberto Corazza
Publication date: 01-04-2012
Publisher: Springer Milan
Published in: Internal and Emergency Medicine / Issue 2/2012
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-011-0719-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology

Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma

Validation of the Italian version of a new coma scale: the FOUR score

Bringing new players into the field: onco-pharmacovigilance in the era of cardio-oncology

Hypokalemia-induced T–U fusion

Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials